Building clean energy infrastructure: Roadblocks, tradeoffs, and solutions

LIVE

Building clean energy infrastructure: Roadblocks, tradeoffs, and solutions
Register
Register

September

21
2011

11:00 am EDT - 12:00 pm EDT

Past Event

Brookings Roundtable on Active Medical Product Surveillance: Overview of Additional Sentinel Activities

Wednesday, September 21, 2011

11:00 am - 12:00 pm EDT

The Brookings Institution
Live Webinar

1775 Massachusetts Ave., NW
Washington, DC

The third and concluding webinar of the Sentinel Initiative 101 Series provided overviews of the Federal Partners Collaboration, the Observational Medical Outcomes Partnership (OMOP), and the Brookings Institution’s convening activities.

The webinar featured presentations from Melissa Robb, Project Director for the Sentinel Initiative, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration; Paul Stang, Senior Director of Epidemiology, Johnson & Johnson, and Principal Investigator at OMOP; and Josh Benner, Fellow in Economic Studies and Managing Director, Engelberg Center for Health Care Reform at Brookings. Presentations provided an overview of each activity and defined each activity’s role within the broader Sentinel Initiative.
 

Brookings Roundtable on Active Medical Product Surveillance: Overivew of Additional Sentinel Activities

Agenda

  • September 21
    • Brookings Roundtable on Active Medical Product Surveillance: Overview of Additional Sentinel Activities

      11:00 am - 12:00 pm

      The final webinar of the series provided additional detail about FDA’s other activities informing the Sentinel Initiative. Members of FDA’s Core Team spoke about the Federal Partners Collaboration; Paul Stang, from Johnson & Johnson and the Observational Medical Outcomes Partnership (OMOP), gave an update on OMOP’s accomplishments and future plans; and Joshua Benner, from the Engelberg Center for Healthcare Reform at Brookings, provided an overview of Brookings Convening Activities.  

      JR
      Judy Racoosin Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research
      PS
      Paul Stang Johnson & Johnson and the Observational Medical Outcomes Partnership
      JR
      Judy Racoosin Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research
      PS
      Paul Stang Johnson & Johnson and the Observational Medical Outcomes Partnership